TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Logo

The stock of Tracon Pharmaceuticals Inc (NASDAQ:TCON) registered a decrease of 6.73% in short interest. TCON’s total short interest was 134,400 shares in January as published by FINRA. Its down 6.73% from 144,100 shares, reported previously. With 120,500 shares average volume, it will take short sellers 1 days to cover their TCON’s short positions. The short interest to Tracon Pharmaceuticals Inc’s float is 0.93%.

The stock decreased 0.01% or $0.0001 during the last trading session, reaching $0.8199. About 156,291 shares traded. TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) has declined 63.33% since January 11, 2018 and is downtrending. It has underperformed by 63.33% the S&P500.

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration , and fibrotic diseases. The company has market cap of $24.49 million. The Company’s lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for soft tissue sarcoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; and Phase I/II clinical trials for wet AMD. It currently has negative earnings. The companyÂ’s other product candidates comprise TRC102, a small molecule that is in Phase II clinical trials for mesothelioma, Phase II clinical trials for glioblastoma, Phase I clinical trial for solid tumors and lymphomas, as well as Phase I clinical trial for lung cancer; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trials for the treatment prostate cancer.

Another recent and important TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) news was published by Seekingalpha.com which published an article titled: “Amgen Inc. 2018 Q1 – Results – Earnings Call Slides – Seeking Alpha” on April 25, 2018.

– Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *